世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

欧州の疼痛管理治療薬市場予測 2019-2027年

EUROPE PAIN MANAGEMENT DRUGS MARKET FORECAST 2019-2027

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2019年1月US$1,250
シングルユーザライセンス(印刷不可PDF)
83

サマリー

この調査レポートは欧州の疼痛管理治療薬市場を分析・予測したInkwood Researchの市場調査報告書です。

Overview

KEY FINDINGS
The European market for pain management drugs is growing at a CAGR of 3.96% during the forecasting years 2019-2027. The United Kingdom, Germany, France, Italy, Spain & the collective countries from the Rest of Europe are considered for the market study. The availability of sophisticated treatment options has led to an increase in the geriatric population who are more dependent on pain management medications.
MARKETING INSIGHTS
Rising cases of cancer pain indication are expected to drive the European market during the forecasting period. Also, opioids drugs will have the highest sales in the Europe market shortly. Major market players in Europe are exhausting advanced technology for the developing abuse-deterrent drugs due to the increase in the number of drug abuse cases in the region. The mounting numbers of surgical procedures coupled with growing healthcare expenditure will be driving the market growth in Germany, whose market is expected to be the dominating one in terms of revenue by the end of 2027.

COMPETITIVE INSIGHTS

The major competing companies in the Europe pain management market are Daiichi Sankyo, Inc., Novartis, Egalet Corp., Eli Lilly and Company, Purdue Pharma L.P., Insys Therapeutics, Inc., GlaxoSmithKline, Abbott Laboratories, Hikma Pharmaceuticals PLC, Johnson & Johnson, Acura Pharmaceuticals, Inc., Lupin Ltd., Pfizer, Inc., Merck & Co., Inc. and Cipher Pharmaceuticals Inc.



 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る